

Kwality Pharmaceuticals Africa Limitada,

Mozambique, Maputo Province, City Of Matola

Balance Sheet As On 31st March, 2020

	Particulars	Figures as at the end of 31/03/2020
		Rs.
A	EQUITY AND LIABILITIES	
1	Shareholders' funds	
	(a) Share capital	8,867,500.00
	(b) Reserves and surplus	-21,338,185.04
	(b) Money Received against share warrents	-
2	Share application money pending allotments	-
3	Non-current liabilities	
	(a) Long-term borrowings	26,630,921.58
	(b) Deferred tax liabilities (net)	-
	(c) Other Long Term Liabilities	-
	(d) Long term provision	-
4	Current liabilities	
	(a) Short Term Borrowings	-
	(b) Trade payables	
	(A) total outstanding dues of micro enterprises and small enterprises	-
	(B) total outstanding dues of Creditors other than micro enterprises and small enterprises	21,031,547.01
	(c) Other current liabilities	1,455,488.67
	(d) Short-term provisions	-
	TOTAL	36,647,272.22
B	ASSETS	
1	Non-current assets	
	(a) (i) Property, Plant and Equipment	10,588,799.30
	(ii) Intangible assets	-
	(iii) Capital Work in progress	-
	(iv) Intangible Assets under Development	
	(b) Non-current investments	
	(c) Deferred Tax Assets	-
	(d) Long term loans and Advances	
	(e) Other Non Current Assets	
2	Current assets	
	(a) Current Investments	-
	(b) Inventories	-
	(c) Trade receivables	20,890,934.16
	(d) Cash and cash equivalents	3,918,779.97
	(e) Short-term loans and advances	1,248,758.79
	(f) Other Current Assets	-
	TOTAL	36,647,272.22

For Kwality Pharmaceuticals Africa Limitada

Sd/-
Ramesh Arora
Director

Sd/-
Rajendra Singh Golan
Director

Kwality Pharmaceuticals Africa Limitada,
Mozambique, Maputo Province, City Of Matola

STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31st MARCH 2020

	Particulars	Figures for the year ended 31/03/2020
		Rs.
I	Revenue from operations	15,298,821.61
II	Other Income	1,089,892.60
III	Total Income (I+II)	16,388,714.20
IV	Expenses	
	(a) Cost of materials consumed	-
	(b) Purchase of Stock in Trade	9,162,472.30
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	45,780.00
	(d) Employee benefits expenses	2,454,848.26
	(e) Finance costs	3,698,738.00
	(f) Depreciation and amortisation expenses	392,537.08
	(g) Other expenses	2,863,050.74
	Total Expenses	18,617,426.38
V	Profit before exceptional and extraordinary item and tax	(2,228,712.17)
VI	Exceptional Items	-
VII	Profit before extraordinary item and tax	(2,228,712.17)
VIII	Extraordinary Items	-
IX	Profit before Tax	(2,228,712.17)
X	Tax Expense:	
	(a) Current tax expense	16,851.37
	(b) Deferred tax	-
	(c) Income tax relating to previous year	-
XI	Profit / (Loss) for the period from continuing operations	(2,245,563.55)
XII	Profit / (Loss) from discontinuing operations	-
XIII	Tax from discontinuing operations	-
XIV	Profit/ (Loss) from discontinuing operations	-
XV	Profit/ (Loss) for the Period	(2,245,563.55)
XVI	Earning per equity share:	
	(1) Basic	-
	(2) Diluted	-

For Kwality Pharmaceuticals Africa Limitada

Sd/-
Ramesh Arora
Director

Sd/-
Rajendra Singh Golan
Director